Brief: Amgen Says Dazodalibep Meets Primary Endpoint In Phase 3 Sjögren's Disease Trial
22/09/2026 14:00
BRIEF-Amgen Says Dazodalibep Meets Primary Endpoint In Phase 3 Sjögren's Disease Trial Sept 22 (Reuters) - Amgen Inc AMGN.O:
AMGEN: PHASE 3 OASIZ 303 STUDY OF DAZODALIBEP IN MODERATE-TO-SEVERE SYMPTOMATIC SJÖGREN’S DISEASE EXPECTED TO COMPLETE IN Q4 2026
AMGEN: DAZODALIBEP MEETS PRIMARY ENDPOINT IN PHASE 3 SJÖGREN'S DISEASE TRIAL
AMGEN: DAZODALIBEP SHOWED STATISTICALLY SIGNIFICANT & CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC DISEASE ACTIVITY
Further company coverage: AMGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amgen
See all newsUS RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Corrected: Amgen drug combined with immunotherapy extends survival in lung cancer trial
US RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk Southern
Eli Lilly hits record high as healthcare stocks rally